Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Yamanouchi, Ono establish codevelopment and marketing agreement for bisphosphonate

Feb. 18, 1999

Preliminary results of testosterone replacement gel reported

Feb. 18, 1999

Sildenafil safe and effective in the treatment of ED in diabetic men

Feb. 17, 1999

ZD-4522 enters accelerated phase III trial program

Feb. 16, 1999

Cellegy initiates clinical trial with transdermal testosterone gel

Feb. 15, 1999

Neurogen and Pfizer collaborate on development of NPY receptor ligands

Feb. 12, 1999

Genentech to withdraw support from pimagedine development

Feb. 11, 1999

Urologix's Targis System superior to alpha-blockers in BPH therapy

Feb. 11, 1999

Cathepsin L inhibitor isolated by Yamanouchi

Feb. 10, 1999

G120K-PEG: a specific renal GHR antagonist for the treatment of diabetic kidney disease

Feb. 10, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...